Key result
An integrated, patient-centered approach combining optimized guideline-directed medical therapy with timely interventional strategies is essential for managing patients with coexisting valvular heart disease and heart failure.
Answers are grounded in this paper and cite their sources.
Captured external expert commentary on this paper, strongest first. Original sources are linked where available.
“Initially targeting 600 patients, the trial was scaled down to 178 because of slow enrollment and funding constraints, which reduced its statistical power to detect meaningful differences. Moreover, the original design called for a primary analysis at 1 year; however, the follow-up period was extended, diluting the ability to capture early differences in clinical outcomes.”
“We should not change the current guidelines. I think it is worthwhile to wait for moderate aortic stenosis to become severe in symptomatic heart failure patients before you expose these patients to a TAVR. That said, in patients who have recurring symptoms that are difficult to control medically, those might be good candidates for a preemptive TAVR. So it's a selected group of patients.”
“It's going to give me data to ask my interventional colleagues to proceed earlier because the procedure is safe, and there's no downstream safety issues. There was a huge rate of development of [severe] aortic stenosis. So patients will need careful follow-up, but these patients are frail, elderly. Frequent follow-up is difficult and costly. And if you can get your average 77-year-old patient to do a dobutamine stress test, you're a better physician than I am. They hate the dobutamine stress test.”
Expert opinion reviews integrated medical and transcatheter valve therapies in heart failure, highlighting benefits of earlier intervention alongside drug optimization.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Généreux et al. (2024) conducted a review in Valvular heart disease and heart failure. Combined guideline-directed medical therapy and interventional therapies was evaluated. An integrated, patient-centered approach combining optimized guideline-directed medical therapy with timely interventional strategies is essential for managing patients with coexisting valvular heart disease and heart failure.
Synapse has enriched 10 related papers. Consider them for comparative context: